Recent studies support the hypothesis that Alzheimer disease (AD)-associated amyloid-beta protein (AA) may induce apoptosis mediated by a caspase cascade. To assess whether mRNA levels of caspase-3, 7, 8 and 9 change in AD brain, and whether these changes correlate with neurofibrillary tangles, AA 40 or AA 42 protein levels or senile plaques, 25 AD and 21 non-demented control brains were examined. Elevated mRNA levels of caspases-7 and 8 measured by a quantitative PCR method were observed in the AD temporal neocortex as compared to the control brains. No significant differences were noticed in levels of caspases-3 or 9 between AD and control brains. Multiple regression analysis demonstrated that, within subjects, the mRNA levels of caspase-8 strongly correlated with both caspse-3 and caspase-7 independently of postmortem interval. Further, there was a strong positive correlation of caspase-8 levels with formic acid extractable AA42 levels. Our results suggest that the transcriptional activation of key components of the apoptotic cascade correlates with accumulation of AA 42. Thus, a principal caspase pathway from caspase-8 to caspase-3 and/or 7 may contribute to neuron loss in AD brain.
INTRODUCTION
The contribution of apoptosis to neurodegerative disorders including Alzheimer disease (AD) has been a matter of much debate (1) . Recent studies suggest that apoptosis in AD can be induced by amyloid-beta protein (AA), playing a central role in AD pathogenesis, to interact with several different neuronal cell surface receptors (2 Y 5) . Although the extent of amyloid deposition in AD brains containing abundant AA tends to correlate poorly with total neuron loss (6, 7) , plaques are associated with local disruption of neurons in both AD and mouse models of APP overexpression (8, 9) . Activation of caspase-8 has a crucial role in apoptosis induced by AA in in vitro studies (10, 11) . Moreover, recent studies also show that tau can be cleaved by caspase-3 and contribute to neurofibrillary tangles (12Y 15) , and that caspases-3, 8 or 9 are activated in AD brain (16, 17) . These findings raise the possibility that the accumulation of AA in the brain parenchyma in AD may render neurons susceptible to death via caspase-mediated apoptosis.
Caspases are cysteine proteases and the central regulators of apoptosis. Initiator caspases, such as caspase-2, 8 and 9, are closely linked to pro-apoptotic signals. Caspase-8 is the initial caspase activated by ligand binding to specific death receptors on the cell surface. Caspase-9 is activated in another apoptotic pathway emerging from mitochondrial stress. Once these upstream caspases are activated, they cleave and activate downstream effector caspases, such as caspase-3, 6 and 7, which in their turn cleave cytoskeletal and nuclear proteins to induce apoptosis (18, 19) . Caspase activation occurs via proteolytic cleavage of pro-caspase molecules, leading to relatively short-lived protein products. In our hands, these proteolytic products representing activated caspases could not be reproducibly identified in postmortem human brain samples by Western blot analysis, despite their ready observation in model systems such as cells undergoing apoptosis. We therefore approached the question of caspase involvement in the AD process by assaying a potentially longer-lived signature of the apoptotic process, transcriptional regulation of caspase mRNA.
In the present study, we therefore examined temporal cortex from 25 AD and 21 non-demented control brains to determine whether mRNA of caspase-3, 7, 8 and 9 are altered in AD, and if so whether these changes are correlated with the extent of any neuropathological changes. Further, limbic cortex including CA1 of hippocampus and layers I and II of entorhinal cortex, which are vulnerable to AD pathology, were also selectively microdissected to measure these caspase mRNA levels in 4 AD and 4 control brains.
MATERIALS AND METHODS

Human Brain Samples
Rapidly frozen (j80-C) temporal cortex tissue from 25 AD (78.4 T 7.1 [mean T SD] years old) and 21 age matched controls (81.2 T 8.2 years old) was obtained from the brain banks at Massachusetts General Hospital, Harvard Brain Bank, and the University of Maryland. The pathological diagnosis of AD was established using the Consortium to Establish a Registry for Alzheimer Disease (CERAD) (20) and the Neuropathological staging of Alzheimer-related changes (21) . The mean age at onset of the AD group was 67.5 T 8.0 and the average disease duration was 11.1 T 4.1 years. All of the control brains were neuropathologically normal. The mean postmortem interval for AD and control groups were 12.6 T 5.8 hours and 16.8 T 5.8 hours, respectively (not significantly different). Approximately 50 to 100 mg of tissue from temporal neocortex gray matter area 20 was dissected from each case for quantitative PCR measurement and 100 to 200 mg of the same tissue was used for ELISA measurements. The procedure was performed under strict RNA-se free conditions, taking care to avoid underlying white matter. Further, 4 AD and 4 controls were selected to measure caspase mRNA levels in hipppocampal regions, which are vulnerable region in AD. CA1 in hippocampus and layer I and II in entorhinal cortex were also microdissected from each case.
Preparation of Total RNA and cDNA
Approximately 50 to 100 mg of tissue was homogenized in Trizoli and total RNA was prepared according to the manufacturer's instructions (Invitrogen, Carlsbad, CA). Briefly, brain tissue was homogenized in 1000 KL of Trizoli reagent, and 200 KL of chloroform was added to the samples. After a brief centrifugation to separate the aqueous phase, 500 KL of isopropanol was added and the mixture was placed on dry ice for 15 minutes. The samples were then centrifuged at 4-C for 15 minutes at 12,000 g. This precipitated total RNA into a pellet that was subsequently washed twice with 500 KL of 75% ethanol. After the second wash, the pellet was dried and solubilized in 20 KL molecular biology grade-water (Eppendorf, Hamburg, Germany). Five to 8 Kg of total RNA was treated with 5 U RNAse-free DNAse I (RQ1, Promega, Madison, WI) for 15 minutes at 37-C. After the DNAse treatment, the RNA was re-extracted with phenol/chloroformisoamyl alcohol and quantified using a spectrophotometer (Eppendorf). RNA integrity was assessed by Agilent 2100 Bioanalyzer\ (Agilent Technologies, Palo Alto, CA). All cases used for quantitative PCR had RNAs that yielded 2 sharp ribosomal 18S and 28S bands. First-strand cDNA synthesis was carried out on 2 Kg of the total RNA from each sample with Superscript IIi (Invitrogen) first-strand synthesis kit for RT-PCR according to the manufacturer instructions. All the samples were equilibrated so that the final concentration of cDNA yielded by the first strand synthesis reaction was 3 ng/KL.
Quantitative PCR
Experimental wells containing 12.5 KL of SYBR\ Green PCR Master Mix (Applied Biosystems, Foster City, CA) were run in triplicate in 96-well plates. Quantitative PCR was carried out on the iCycler\ (BioRad, Hercules, CA) according to the SYBR\ green method. For each reaction 3 ng of cDNA was used in a 25 KL reaction containing 5 pmol of each primer and 12.5 KL of SYBR\ Green PCR Master Mix (Applied Biosystems). Forward and reverse primers were designed using the tools available through the MIT Whitehead Institute web page (http://wwwgenome.wi.mit.edu/cgi-bin/primer/primer3.cgi). Primer sets were selected to amplify small (100Y 300 bp) amplicons for each candidate mRNA and to have high PCR efficiencies (80Y95% preferably). The sequences of the primers used for caspase-3 were 5 ¶ and AACCTCAGGGAAACATTCAG-3 ¶ and 5 ¶-GGCT CAGAAGCACACAAAC-3 ¶, for caspase-7 were 5 ¶-GAA G A G G C T C C T G G T T T G T G -3 ¶ a nd 5 ¶-T C A T G G A AGTGTGGGTCATC-3 ¶, for caspase-8 were 5 ¶-GGATG CCTTGATGTTATTCC-3 ¶ and 5 ¶-AGTTCCCTTTCCAT CTCCTC-3 ¶, and for caspase-9 were 5 ¶-TTCCCAGGTTTTG TTTCCTG-3 ¶ and 5 ¶-ACCCTAAGCAGGAGGGACTG-3 ¶. BLAST searches (22) for the primer sequences revealed no matches other than for the specific gene being examined. Quantitative PCR amplification for all the caspases proceeded to preincubate at 94-C for 6 minutes, followed by 50 cycles at 94-C for 30 seconds, at 55-C for 30 seconds, and at 72-C for 45 seconds. The specificity of each candidate PCR amplicon was evaluated by melting curve (Tm) analysis or Agilent 2100 Bioanalyzer\ (Agilent Technologies) and direct sequencing. A standard curve was created for each gene using known concentrations of reference cDNA or cDNA clones. All primer pairs amplified a single peak of fluorescence by melt curve analysis. This curve was used to both calculate the primer set efficiency for each particular experiment, and to quantitate products. Each transcript of interest was quantified using a modification of the $Ct method (23), which interpolates the Ct back into the standard curve with an algorithm embedded in the software provided with the iCycler.
AA40, AA42, Synaptophysin, GFAP and BDNF Protein Levels by ELISA AD-related neuronal, glial and neurotrophic markers, for AA40, AA42, synaptophysin, glial fibrillary acidic protein (GFAP) and brain-derived neurotrophic factor (BDNF) protein levels were measured by ELISA. Approximately 100 to 200 mg of brain tissue from temporal cortex was extracted in 10 KL/mg of Tris buffer (Tris/HCl 50 mM pH 7.2, NaCl 200 mM, EDTA 2 mM) with protease inhibitor cocktail (Complete; Roche, Indianapolis, IN). After centrifugation at 21,000 g at 4-C for 5 minutes, the pellet was homogenized in 70% formic acid and recentrifuged (44,000 g, 4-C, 5 minutes), and the resulting formic acid-extracted supernatant was neutralized with 1 M tris buffer (pH 11.0), representing the formic acid-extracted AA fraction. The ELISA for AA utilized capture antibody BNT 77 (monoclonal anti-AA 11-28; Takeda Chemical Industries, Osaka, Japan) with the HRP-linked detector antibodies BA27 (monoclonal anti-AA40; Takeda) or BC05 (monoclonal anti-AA42; Takeda). QuantaBlu was used as the fluorescent HRP substrate, and the fluorescence intensity was measured by the Wallac Victor 2 plate reader. Synthetic human AA40 and AA42 peptide (Backem, King of Prussia, PA) were used as standards (24, 25) . For the other measurements for ELISA, the tissues were extracted in tris buffer with Triton X-100 at a concentration of 0.1% and the supernatant was used. Synaptophysin levels were measured using capture antibody mAb329 (monoclonal IgM anti-synaptophysin; Chemicon, Temecula, CA) (26) and a biotinylated detector antibody (monoclonal IgG anti-synaptophysin; Progen, Wieblingen, Germany). Serial dilutions of a control temporal cortex were used as standard (27) . GFAP levels were measured using a polyclonal anti-GFAP capturing antibody (SigmaAldrich, St. Louis, MO) and a monoclonal anti-GFAP detector antibody (Sigma-Aldrich). The ELISA for BDNF utilized the capture MAB848 (monoclonal mouse anti-BDNF, R&D Systems, Minneapolis, MN) as capture antibody and biotinylated BAM648 (R&D Systems) as detector antibody. All other details were described in our earlier reports (27, 28) . Data for some of the protein levels utilized in this study have been presented previously (24, 25, 27, 28) .
Statistical Analysis
Statistical analyses were carried out with the statistical software package SPSS version 10.0. Continuous variables were compared by Mann-Whitney U-test because caspases mRNA levels were not normally distributed. Pearson 
RESULTS mRNA Levels of Caspases by Quantitative PCR in Temporal Neocortex of AD and Control Brains
We first assessed whether mRNA levels were sensitive to postmortem interval in the control or AD groups. As shown in Figure 1 , importantly, caspase-3, 7, 8 and 9 mRNA levels did not correlate with postmortem intervals. mRNA levels of caspases measured by quantitative PCR method in this study are summarized in Table 1 and Figure 2 . The largest change we observed was for caspase 8. Average mRNA levels of caspase-8 were about 2-fold higher in AD brains compared to control brains when mRNA levels were normalized for the amount of total RNA in the sample (p = 0.03, Fig. 2C ). Statistical significance was observed for both caspase-7 and 8 when the values were normalized for the amount of GAPDH (caspase-7: p = 0.003; caspase-8: p = 0.003, Fig. 2B, C) . However, no significant difference was noticed in levels of caspases-3 and 9 between disease and control brains with or without normalization by GAPDH (Fig. 2A, D) .
We next examined whether the levels of caspase-3, 7, 8 and 9 co-varied to test the possibility that their transcription was co-regulated. As shown in Table 2 , there were clear inter-relationships among the values for caspases. A hierarchical multiple regression analysis assessing the relative contribution of the other caspases and GAPDH to caspase-8 showed that caspase-7 levels had the strongest correlation (pr = 0.74, p G 0.0001) and caspase-3 levels were the second predictor of caspase-8 (pr = 0.68, p = 0.0032). No relationship was detected with GAPDH, indicating that these effects are not related to RNA quality. Additionally, the caspase-8 levels correlated significantly but weakly with age The caspase-7 and 8 mRNA levels, which were found to be higher in AD compared to control, were then analyzed to uncover relationships with the marker protein levels in AD. There was a strong positive correlation of caspase-8 levels with formic acid extractable AA42 levels (p = 0.002, Fig. 4D ), but not with the other protein levels of AA, Tris extractable AA40 and AA42, and formic acid AA40 (Fig. 4A YC) . There was no correlation between caspase-8 levels and synaptophysin (p = 0.44, Fig. 5A ). The GFAP levels correlated significantly with the caspase-8 levels (p = 0.046, Fig. 5B ). The BDNF levels did not correlate with caspase-8 levels (p = 0.19, Fig. 5C ). Caspase-7 levels did not correlate with any of the indices.
mRNA Levels of Caspases in Limbic Cortex of AD and Control Brains
Several additional samples were examined from 4 AD and 4 control cases to confirm and extend these observations. To determine whether co-ordinate changes in caspase mRNA levels could be observed in a different brain area, mRNA levels were measured in microdissected area, CA1 of the hippocampus and layer I and II of entorhinal cortex of AD and control brain. Caspase-3 and GFAP mRNA levels in CA1 of AD brains were higher than those of control brains (caspase-3: p = 0.04, Fig. 6A ; GFAP: p = 0.02). Caspase-3, 7, 8 and 9 mRNAs were detectable from all the brain regions in AD (Fig. 6 ). Multiple regression analysis was conducted to assess interaction between caspse-3 levels and the other caspases and GAPDH in the limbic cortex. The caspase-3 mRNA levels correlated with caspase-7 (pr = 0.55, p = 0.01) and caspase-8 (pr = 0.65, p = 0.002) mRNA levels, echoing results from temporal neocortex.
DISCUSSION
These results give rise to the hypothesis that caspase transcriptional stimulation could be engaged by the presence of an aggregated form of AA, which ultimately links upstream caspase-8 as an initiator to downstream caspases-3 and 7 as effectors to induce apoptosis.
Although caspase cascades are usually thought of as being regulated at the post-translational level via stimulusinduced cleavage of pro-forms of the enzymes, it is possible that certain stimuli lead also to upregulation of caspase transcription (29, 30) . In our initial studies, we found that postmortem human brain frequently contained numerous caspase immunoreactive bands on Western blot, making interpretation of the levels of caspase activation difficult. We therefore examined caspase mRNA levels to determine if chronic neurodegeneration in AD altered expression of upstream (caspase-8 or 9) or downstream (casapase-3 or 7) mRNAs.
Caspase-8 transcriptional upregulation has been reported in a variety of circumstances, often in the setting of cytokine mediated signaling (31 Y33); in these settings caspase-8 mRNA and downstream caspases can be coregulated (30, 31) . Our current data are consistent with prior reports of activation of caspase-8 in the AD brain (17) and further show a coordinated upregulation of caspase-8, caspase-7, and caspase-3 in these samples. Whether this is neuronal or glial cannot be directly ascertained from these data. However, assessment of subdissected layer I and layer II of temporal (entorhinal) cortex indicate readily detectable caspase and GFAP mRNA levels in both lamina, consistent with a contribution from both glial and neuronal elements (34) . However, we interpret the positive correlation of GFAP levels in temporal neocortex with caspase-8 mRNA levels as representing 2 indices of cortical degeneration, rather than as evidence necessarily favoring glial overproduction of caspases.
The caspase-8 initiated cleavage of substrates requires activation of caspase-8 by ligand binding to a specific receptor on the cell surface. AA has been shown to participate as a ligand to induce apoptosis by interacting with neuronal receptors, although the exact mechanisms remain uncertain. Yaar et al demonstrated that p75-kD neurotrophin receptor, a family member of the tumor necrosis factor receptor superfamily, can specifically bind AA and induce apoptosis (4). Lorenzo et al showed that the amyloid precursor protein also interacts with AA to induce neuronal cell death (5) . Other studies provide evidence that AA activates the Fas ligand pathway, probably leading to activation of caspase-8 (35, 36) . In accord with these observations, active fragments of caspase-8 have been detected in neurons of AD (17, 37) .
It should be noted that only the aggregated, fibrillar form of AA markedly increased its binding to cell surface receptors and led to cytotoxicity in vitro (4, 5) . Our data also show a correlation between formic acid extractable AA42 and caspase-8 expression, although whether or not there is a direct relationship between caspase-8 activation and caspase-8 mRNA levels remains unknown. Further, microglial activation has been reported to be associated with the presence of amyloid plaques and can be induced experimentally by AA (38) . This AA induced microglial activation results in the secretion of TNF-> and other factors (39) that can also induce neuronal apoptosis via a caspase cascade (40Y 42).
We also examined the question of whether co-ordinate regulation of caspase transcripts occurs in limbic cortex, a second brain region undergoing neurodegeneration in AD. Although the number of brain samples from limbic cortex was too small to compare AD to control populations, the statistical power to detect relationships among transcripts within cases was sufficient to detect correlations between caspase 3, 7 and 8, analogous to our finding in temporal neocortex (43) , and supporting the idea that caspases are coordinately regulated.
In conclusion, our findings provide evidence for the possible involvement of a coordinated caspase response to AA deposition in AD. Important questions for future studies will be to understand the signaling mechanism leading to this pattern of transcriptional upregulation, and to determine
